LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 1476 | 1640 | 3788 | 0.4329 | 0.0802 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 1476 | 1475 | 3731 | 0.3953 | -0.0009 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 1476 | 1445 | 3796 | 0.3806 | -0.0158 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 1 | M07 | 72 | hr | 1476 | 985 | 3788 | 0.2600 | -0.2576 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 2 | M07 | 72 | hr | 1476 | 1088 | 3731 | 0.2916 | -0.2042 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 3 | M07 | 72 | hr | 1476 | 1186 | 3796 | 0.3124 | -0.1487 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 1 | M24 | 72 | hr | 1476 | 3297 | 3788 | 0.8702 | 0.8056 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 2 | M24 | 72 | hr | 1476 | 2957 | 3731 | 0.7925 | 0.6808 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 3 | M24 | 72 | hr | 1476 | 2840 | 3796 | 0.7480 | 0.6162 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 1 | M23 | 72 | hr | 1476 | 3439 | 3788 | 0.9077 | 0.8625 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 2 | M23 | 72 | hr | 1476 | 3273 | 3731 | 0.8772 | 0.8133 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 3 | M23 | 72 | hr | 1476 | 3240 | 3796 | 0.8534 | 0.7803 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 1 | M22 | 72 | hr | 1476 | 3586 | 3788 | 0.9465 | 0.9207 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 2 | M22 | 72 | hr | 1476 | 3211 | 3731 | 0.8606 | 0.7876 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 3 | M22 | 72 | hr | 1476 | 3479 | 3796 | 0.9163 | 0.8758 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 1476 | 3445 | 3788 | 0.9093 | 0.8649 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 1476 | 3237 | 3731 | 0.8676 | 0.7984 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 1476 | 3337 | 3796 | 0.8789 | 0.8193 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 1 | M20 | 72 | hr | 1476 | 3294 | 3788 | 0.8694 | 0.8044 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 2 | M20 | 72 | hr | 1476 | 3152 | 3731 | 0.8448 | 0.7630 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 3 | M20 | 72 | hr | 1476 | 3402 | 3796 | 0.8961 | 0.8452 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 1 | M19 | 72 | hr | 1476 | 1804 | 3788 | 0.4762 | 0.1587 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 2 | M19 | 72 | hr | 1476 | 1857 | 3731 | 0.4977 | 0.1869 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 3 | M19 | 72 | hr | 1476 | 1912 | 3796 | 0.5036 | 0.2088 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 1 | N12 | 72 | hr | 1476 | 3244 | 3413 | 0.9504 | 0.9176 |